Hangzhou Sciwind Biosciences Co., a pre-commercial biopharmaceutical company focusing on developing innovative therapies to treat metabolic diseases, today announced a licensing and collaboration ...

Now that Novo Nordisk is the world’s weight-loss juggernaut, will it have to betray its first patients—type 1 diabetics?

EY—the professional services firm originally known as Ernst & Young—reports the dollar value of biopharma M&A deals nosedived ...

Ramesh and Rajeev Juneja of Mankind Pharma fought popular perceptions and made large acquisitions, focussed on specialty ...

On Jan. 1, North Dakota became the first state in the country where access to drugs like Wegovy is part of the EHB package. About 55,293 of North Dakota's 784,000 residents had coverage through fully ...

At the moment AZ's clinical-stage pipeline only lists one candidate for obesity, its large-molecule GLP-1/glucagon dual agonist cotadutide which has reached mid-stage testing for overweight and ...

For some patients, injectables, such as insulin or a glucagon-like peptide-1 (GLP-1 ... Mounjaro is a single-molecule treatment that can be self-injected subcutaneously into the abdomen, thigh ...

The series A fundraising is the biggest ever for a European biotech firm, according to the data provider PitchBook.

Jan. 15, 2025 — A cutting-edge molecular approach provides a detailed picture of the biological pathways associated with childhood obesity and metabolic dysfunction, and identifies environmental ...

Dec. 18, 2024 — Researchers studied oxygen treatment as a potential therapy to target specific cells linked to the development of cardiovascular and metabolic disorders like high blood pressure ...

Endothelial dysfunction is one manifestation of the many changes induced in the arterial wall by the metabolic abnormalities accompanying diabetes and insulin resistance. In type 1 diabetes ...

After hours: January 10 at 7:51:27 p.m. EST ...